RAD23D, like other RAD23 proteins, contains:
N-terminal ubiquitin-like (UBL) domain: Facilitates interaction with the 26S proteasome via RPN10.
Rad4/XPC-binding domain: Stabilizes DNA damage recognition in NER.
C-terminal ubiquitin-associated (UBA) domains: Bind polyubiquitin chains to target substrates for degradation.
RAD23D contributes to global genomic NER by:
Stabilizing XPC (Rad4 in yeast): Enhances DNA damage binding and repair efficiency .
Complementing repair defects: Partial repair activity in rad23 mutants requires Rad23 and Rad4 synergy .
RAD23D acts as a ubiquitin receptor:
Binds 'Lys-48'-linked polyubiquitin chains: Prefers multiubiquitin tags over single chains .
Interacts with RPN10: Facilitates substrate delivery to the 26S proteasome .
Drought tolerance in plants: MdRAD23D1 (apple homolog) interacts with MdPRP6 to modulate stress-induced proteolysis .
Neurodegeneration models: RAD23 knockdown accelerates degradation of toxic proteins (e.g., mutSOD1, mutTDP-43) in ALS models .
While RAD23D-specific antibodies are scarce, polyclonal antibodies targeting the RAD23 family (A-D) are available:
Note: RAD23D-specific antibodies are not explicitly listed in current databases. Researchers often use cross-reactive antibodies validated for broader RAD23 family detection.
Plant studies: Use anti-RAD23A-D antibodies to monitor protein abundance in Arabidopsis under stress .
Human studies: RAD23B-specific antibodies (e.g., BioLegend #8355) distinguish isoforms in proteasome research .
Immunofluorescence: RAD23 proteins localize to the nucleus and cytoplasm, with cell cycle-dependent dynamics .
Isoform specificity: Most antibodies target conserved regions, limiting RAD23D-specific detection.
Functional redundancy: Overlapping roles among RAD23A-D complicate isoform-specific analysis.
Species variation: Plant (e.g., Arabidopsis, apple) and human RAD23 homologs diverge in subcellular localization and stress responses .
Development of RAD23D-specific antibodies: Critical for elucidating isoform-specific roles in NER and stress adaptation.
Structural studies: Cryo-EM or X-ray crystallography to map RAD23D-ubiquitin/proteasome interactions.
Therapeutic targeting: Exploiting RAD23D’s role in proteostasis for neurodegenerative or stress-related diseases .